By Justin Petrone
Though a slowdown in the genome-wide association studies market has led to diminishing sales of its arrays, Illumina is confident that new genotyping chips scheduled to launch next year will restore array revenues, according to a company official.
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Try GenomeWeb Premium now.
Already a GenomeWeb Premium member? Login Now. Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
In a column at Nature, researcher Fyodor Kondrashov worries about the influence of politics on Russian science.
The term 'epigenetics' is being used by quacks to give them a veneer of science, writes Adam Rutherford at the Observer.
The NIH has issued a preliminary guidance for newborn dried blood spot research.
Wired writes that CRISPR could change the world — in many imaginative ways — and whether it will be for the better is still in the air.